drugset / Trial / NCT01562951
Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants
Phase 3
Terminated
15 enrolled
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Abbott · collabTFS Trial Form Support · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will test that individualized treatment in patients with Crohn's Disease in remission or mild clinical activity under immunosuppressants may improve prognosis, rather than just treating flares.
Timeline
- Start
- 2012-10
- Primary completion
- 2014-03
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Adalimumab | Monoclonal antibody | 40 mg | — |